Brokerages expect Xencor Inc (NASDAQ:XNCR) to report $15.65 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Xencor’s earnings. The lowest sales estimate is $10.30 million and the highest is $21.00 million. Xencor posted sales of $6.44 million in the same quarter last year, which indicates a positive year-over-year growth rate of 143%. The firm is scheduled to report its next quarterly earnings results on Tuesday, February 27th.

On average, analysts expect that Xencor will report full year sales of $15.65 million for the current fiscal year, with estimates ranging from $25.30 million to $45.77 million. For the next financial year, analysts anticipate that the business will report sales of $25.33 million per share, with estimates ranging from $19.80 million to $36.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Xencor.

XNCR has been the topic of several recent analyst reports. Canaccord Genuity set a $36.00 price target on Xencor and gave the company a “buy” rating in a research note on Monday, October 23rd. ValuEngine lowered Xencor from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Zacks Investment Research lowered Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, November 11th. Piper Jaffray Companies reissued a “buy” rating and issued a $35.00 price target on shares of Xencor in a research note on Sunday, November 12th. Finally, Cantor Fitzgerald initiated coverage on Xencor in a research note on Wednesday, November 29th. They issued an “overweight” rating and a $33.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. Xencor has an average rating of “Hold” and a consensus target price of $30.80.

In other news, major shareholder John S. Stafford III bought 50,000 shares of the stock in a transaction dated Thursday, November 2nd. The shares were bought at an average cost of $19.58 per share, with a total value of $979,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder John S. Stafford III bought 150,000 shares of the stock in a transaction dated Friday, October 27th. The shares were purchased at an average cost of $19.81 per share, for a total transaction of $2,971,500.00. The disclosure for this purchase can be found here. Insiders have bought 278,535 shares of company stock worth $5,526,936 over the last ninety days. 4.03% of the stock is owned by insiders.

Large investors have recently modified their holdings of the company. Emory University acquired a new position in shares of Xencor during the second quarter worth approximately $1,491,000. Virginia Retirement Systems ET AL raised its position in shares of Xencor by 10.0% during the third quarter. Virginia Retirement Systems ET AL now owns 76,200 shares of the biopharmaceutical company’s stock worth $1,747,000 after purchasing an additional 6,900 shares during the period. State Street Corp raised its position in shares of Xencor by 11.1% during the second quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock worth $23,295,000 after purchasing an additional 110,474 shares during the period. State of Wisconsin Investment Board acquired a new position in shares of Xencor during the second quarter worth approximately $612,000. Finally, Vanguard Group Inc. raised its position in shares of Xencor by 5.6% during the second quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock worth $35,913,000 after purchasing an additional 90,094 shares during the period. 77.50% of the stock is currently owned by institutional investors.

Xencor (XNCR) opened at $22.83 on Friday. Xencor has a 12 month low of $18.55 and a 12 month high of $28.64. The stock has a market capitalization of $1,090.00, a P/E ratio of -22.60 and a beta of 2.09.

TRADEMARK VIOLATION WARNING: “Analysts Expect Xencor Inc (XNCR) Will Post Quarterly Sales of $15.65 Million” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/06/analysts-expect-xencor-inc-xncr-will-post-quarterly-sales-of-15-65-million.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.